Faron Pharmaceuticals Oy (LON:FARN) Hits New 52-Week Low – Here’s What Happened

Faron Pharmaceuticals Oy (LON:FARN)’s share price reached a new 52-week low on Wednesday . The company traded as low as GBX 38 and last traded at GBX 38.70, with a volume of 95836 shares traded. The stock had previously closed at GBX 41.

Faron Pharmaceuticals Oy Stock Performance

The firm has a market cap of £53.57 million, a price-to-earnings ratio of -1.93 and a beta of 1.18. The company has a debt-to-equity ratio of -133.35, a current ratio of 0.84 and a quick ratio of 1.09. The firm has a fifty day simple moving average of GBX 47.19 and a two-hundred day simple moving average of GBX 127.43.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.